Additionally, GSK will relocate its UK R&D headquarters from Stevenage to Cambridge.
GSK's push to speed up drug development, particularly in oncology and respiratory illnesses, follows its second-quarter earnings of 50.5 pence per share, which surpassed analyst forecasts. The company now anticipates that its full-year sales and operating profit will land at the top of its previously guided range.
The cost-cutting initiative comes as GSK prepares for the eventual patent expiration of its blockbuster HIV drug dolutegravir, which has been a significant revenue driver. By reallocating resources, the company aims to mitigate the impact and sustain growth through its expanding pipeline in oncology, vaccines, and respiratory treatments.
A key investor concern is whether GSK can offset the revenue decline when its top-selling HIV medicine dolutegravir loses patent protection. The company stated it remains on track to achieve its 2031 sales goal.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
"We can navigate it, but not only navigate that, but also grow through that period and then accelerate growth on the other side in 2031," Miels told reporters on a call.
Cost reductions will finance the research spending. The cuts will target human resources and commercial operations, particularly divisions marketing older drugs. The company declined to say exactly how many jobs would be eliminated. Implementing the plan will cost £2.4 billion, with most of that expense recorded in 2026 and 2027.
Around 45% of the savings are expected from better procurement practices, 15% from supply chain improvements, and the remainder from moving support functions to higher-margin specialty areas. GSK is not just saving money. It is spending it, too.
The company paid $10.6 billion this year to buy the biotech firm Nuvalent, adding new cancer drugs to its pipeline. The company intends to intensify its focus on oncology, as well as liver diseases and respiratory conditions.
Tony Wood, GSK's chief scientific officer, stated that the company now has multiple drugs in trials for various diseases and has reduced drug development time by 25%. One example is the experimental oncology drug risvutatug rezetecan, called Riz-Rez, currently under investigation for multiple tumor types, among them an aggressive form of small-cell lung cancer.
During the second quarter, GSK's shingles and meningitis vaccines outperformed expectations. GSK intends to investigate whether its Shingrix vaccine can lower the risk of dementia and cardiovascular incidents such as heart attacks.
Investors seem to like the direction. Sean Conroy, an analyst at Shore Capital, said in a note: "GSK is shedding legacy perceptions of being a perennial disappointment, and we believe it is becoming increasingly difficult to dismiss its longer-term growth ambitions."
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
